Fecal microbiota transplantation (FMT) has emerged as a novel therapeutic approach for a variety of gastrointestinal and systemic conditions by restoring microbial diversity and modulating gut microbiota composition. Increasing evidence suggests that the gut microbiota plays a pivotal role in the pathogenesis of metabolic disorders, including obesity, type 2 diabetes (T2D), and non-alcoholic fatty liver disease (NAFLD). FMT, which involves transferring fecal matter from a healthy donor to a recipient, has been shown to influence metabolic homeostasis by altering gut microbiota composition, improving insulin sensitivity, and modulating inflammatory pathways. This review explores the mechanisms underlying the impact of FMT on metabolic health, summarizes the current clinical evidence on its efficacy in treating metabolic disorders, and discusses the challenges and future directions for FMT as a therapeutic strategy for metabolic diseases.
Published Date: 2024-11-30; Received Date: 2024-11-02
